How Recent Clinical Wins and Risks Are Changing the Story for Nektar Therapeutics [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
This reflects sustained confidence in the company's long-term potential. Although the analyst discount rate has inched higher, updated revenue growth assumptions indicate a less severe decline. This suggests improving prospects as new information emerges. Stay tuned to learn how you can continue following key developments shaping the outlook for Nektar Therapeutics. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Nektar Therapeutics. What Wall Street Has Been Saying Analysts have continued to weigh in on Nektar Therapeutics, focusing on critical upcoming catalysts and evolving market and clinical dynamics. Their commentary provides insight into the perceived risks and opportunities influencing the company's valuation and growth outlook. ?? Bullish Takeaways Piper Sandler remains optimistic, highlighting that recent Phase 3 results from a key competitor in atopic dermatitis showed underwhelming efficacy comp
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics (NASDAQ:NKTR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $102.00 price target on the stock.MarketBeat
- Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- Nektar Therapeutics (NASDAQ:NKTR) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NKTR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets [Seeking Alpha]Seeking Alpha
- Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout [Seeking Alpha]Seeking Alpha
NKTR
Earnings
- 11/6/25 - Beat
NKTR
Sec Filings
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- NKTR's page on the SEC website